Log In
BCIQ
Print this Print this
 

Meropen, Merrem, meropenem

  Manage Alerts
Collapse Summary General Information
Company Sumitomo Dainippon Pharma Co. Ltd.
DescriptionIV carbapenem
Molecular Target Penicillin binding proteins (PBP)
Mechanism of ActionCell wall synthesis inhibitor
Therapeutic ModalitySmall molecule

 Product Details
Disease CategoryStandard IndicationIndication DetailsPartnersMilestonesLatest Stage of DevelopmentRegulatory Designation
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$1,575.0M

$725.0M

$850.0M


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

08/24/2016

$1,575.0M

$725.0M

$850.0M

Get a free BioCentury trial today